You are here

Article Text

Article menu
Download PDFPDF
Original Article
Interleukin-8 promoter polymorphism −251A/T is a risk factor for age-related macular degeneration
  1. S V Goverdhan1,2,
  2. S Ennis3,
  3. S R Hannan2,
  4. K C Madhusudhana2,
  5. A J Cree1,
  6. A J Luff2,
  7. A J Lotery1,2
  1. 1
    Clinical Neurosciences Division, Southampton General Hospital, Southampton, UK
  2. 2
    Southampton Eye Unit, Southampton General Hospital, Southampton, UK
  3. 3
    Genetic Epidemiology & Bioinformatics, Human Genetics Division, Southampton General Hospital, Southampton, UK
  1. A Lotery, Clinical Neurosciences Division, Mailpoint 806, Southampton General Hospital, Southampton SO16 6YD, UK; a.j.lotery{at}soton.ac.uk

Abstract

Background/aims: To determine whether four expression-related cytokine polymorphisms are associated with age-related macular degeneration (AMD).

Methods: DNA from 478 cases with AMD and 555 normal controls was genotyped for the pro-inflammatory IL1β −511C/T, IL6 −174C/G, IL8 −251A/T and anti-inflammatory IL10 −1082G/A cytokine polymorphisms using the 5′ nuclease TaqMan® assay for allelic discrimination. Associations with AMD were analysed using allelic frequencies.

Results: The −251A allele of the IL8 promoter gene polymorphism was more prevalent in AMD patients than controls (p = 0.037, OR = 1.21, 95% CI = 1.01 to 1.44). Adjusting for age, sex, body mass index (BMI), current smoking and past smoking status did not alter the AMD association significantly (corrected p value = 0.043, OR = 1.23, 95% CI = 1.0 to 1.50).

Conclusion: The pro-inflammatory homozygous IL8 –251AA genotype is an important risk factor for AMD. This may have implications for future therapy with biological agents that could target this cytokine.

https://doi.org/10.1136/bjo.2007.123190

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Funding: Grant support from Lord Sandberg, Macular Disease Society, Brian Mercer Trust and the Wellcome Trust.

    • Competing interests: None.

    • Patient consent: Informed and written consent was obtained.

    Linked Articles